探索将单细胞 RNA 测序作为福氏内皮性角膜营养不良症临床治疗的决策工具。

IF 18.6 1区 医学 Q1 OPHTHALMOLOGY
Gink N. Yang , Yu B.Y. Sun , Philip Ke Roberts , Hothri Moka , Min K. Sung , Jesse Gardner-Russell , Layal El Wazan , Bridget Toussaint , Satheesh Kumar , Heather Machin , Gregory J. Dusting , Geraint J. Parfitt , Kathryn Davidson , Elaine W. Chong , Karl D. Brown , Jose M. Polo , Mark Daniell
{"title":"探索将单细胞 RNA 测序作为福氏内皮性角膜营养不良症临床治疗的决策工具。","authors":"Gink N. Yang ,&nbsp;Yu B.Y. Sun ,&nbsp;Philip Ke Roberts ,&nbsp;Hothri Moka ,&nbsp;Min K. Sung ,&nbsp;Jesse Gardner-Russell ,&nbsp;Layal El Wazan ,&nbsp;Bridget Toussaint ,&nbsp;Satheesh Kumar ,&nbsp;Heather Machin ,&nbsp;Gregory J. Dusting ,&nbsp;Geraint J. Parfitt ,&nbsp;Kathryn Davidson ,&nbsp;Elaine W. Chong ,&nbsp;Karl D. Brown ,&nbsp;Jose M. Polo ,&nbsp;Mark Daniell","doi":"10.1016/j.preteyeres.2024.101286","DOIUrl":null,"url":null,"abstract":"<div><p>Single-cell RNA sequencing (scRNA-seq) has enabled the identification of novel gene signatures and cell heterogeneity in numerous tissues and diseases. Here we review the use of this technology for Fuchs’ Endothelial Corneal Dystrophy (FECD). FECD is the most common indication for corneal endothelial transplantation worldwide. FECD is challenging to manage because it is genetically heterogenous, can be autosomal dominant or sporadic, and progress at different rates. Single-cell RNA sequencing has enabled the discovery of several FECD subtypes, each with associated gene signatures, and cell heterogeneity. Current FECD treatments are mainly surgical, with various Rho kinase (ROCK) inhibitors used to promote endothelial cell metabolism and proliferation following surgery. A range of emerging therapies for FECD including cell therapies, gene therapies, tissue engineered scaffolds, and pharmaceuticals are in preclinical and clinical trials. Unlike conventional disease management methods based on clinical presentations and family history, targeting FECD using scRNA-seq based precision-medicine has the potential to pinpoint the disease subtypes, mechanisms, stages, severities, and help clinicians in making the best decision for surgeries and the applications of therapeutics. In this review, we first discuss the feasibility and potential of using scRNA-seq in clinical diagnostics for FECD, highlight advances from the latest clinical treatments and emerging therapies for FECD, integrate scRNA-seq results and clinical notes from our FECD patients and discuss the potential of applying alternative therapies to manage these cases clinically.</p></div>","PeriodicalId":21159,"journal":{"name":"Progress in Retinal and Eye Research","volume":null,"pages":null},"PeriodicalIF":18.6000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploring single-cell RNA sequencing as a decision-making tool in the clinical management of Fuchs’ endothelial corneal dystrophy\",\"authors\":\"Gink N. Yang ,&nbsp;Yu B.Y. Sun ,&nbsp;Philip Ke Roberts ,&nbsp;Hothri Moka ,&nbsp;Min K. Sung ,&nbsp;Jesse Gardner-Russell ,&nbsp;Layal El Wazan ,&nbsp;Bridget Toussaint ,&nbsp;Satheesh Kumar ,&nbsp;Heather Machin ,&nbsp;Gregory J. Dusting ,&nbsp;Geraint J. Parfitt ,&nbsp;Kathryn Davidson ,&nbsp;Elaine W. Chong ,&nbsp;Karl D. Brown ,&nbsp;Jose M. Polo ,&nbsp;Mark Daniell\",\"doi\":\"10.1016/j.preteyeres.2024.101286\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Single-cell RNA sequencing (scRNA-seq) has enabled the identification of novel gene signatures and cell heterogeneity in numerous tissues and diseases. Here we review the use of this technology for Fuchs’ Endothelial Corneal Dystrophy (FECD). FECD is the most common indication for corneal endothelial transplantation worldwide. FECD is challenging to manage because it is genetically heterogenous, can be autosomal dominant or sporadic, and progress at different rates. Single-cell RNA sequencing has enabled the discovery of several FECD subtypes, each with associated gene signatures, and cell heterogeneity. Current FECD treatments are mainly surgical, with various Rho kinase (ROCK) inhibitors used to promote endothelial cell metabolism and proliferation following surgery. A range of emerging therapies for FECD including cell therapies, gene therapies, tissue engineered scaffolds, and pharmaceuticals are in preclinical and clinical trials. Unlike conventional disease management methods based on clinical presentations and family history, targeting FECD using scRNA-seq based precision-medicine has the potential to pinpoint the disease subtypes, mechanisms, stages, severities, and help clinicians in making the best decision for surgeries and the applications of therapeutics. In this review, we first discuss the feasibility and potential of using scRNA-seq in clinical diagnostics for FECD, highlight advances from the latest clinical treatments and emerging therapies for FECD, integrate scRNA-seq results and clinical notes from our FECD patients and discuss the potential of applying alternative therapies to manage these cases clinically.</p></div>\",\"PeriodicalId\":21159,\"journal\":{\"name\":\"Progress in Retinal and Eye Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":18.6000,\"publicationDate\":\"2024-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Retinal and Eye Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S135094622400051X\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Retinal and Eye Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S135094622400051X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

单细胞 RNA 测序(scRNA-seq)能够识别许多组织和疾病中的新型基因特征和细胞异质性。在此,我们回顾了该技术在福氏内皮性角膜营养不良症(FECD)中的应用。FECD 是全球最常见的角膜内皮移植适应症。福氏角膜内皮营养不良症具有遗传异质性,可能是常染色体显性遗传,也可能是散发性遗传,而且进展速度各不相同,因此治疗难度很大。单细胞 RNA 测序发现了几种 FECD 亚型,每种亚型都有相关的基因特征和细胞异质性。目前,FECD 的治疗方法主要是外科手术,手术后使用各种 Rho 激酶(ROCK)抑制剂来促进内皮细胞的新陈代谢和增殖。一系列针对 FECD 的新兴疗法,包括细胞疗法、基因疗法、组织工程支架和药物疗法,都已进入临床前和临床试验阶段。与基于临床表现和家族史的传统疾病管理方法不同,利用基于 scRNA-seq 的精准医疗来靶向 FECD 有可能准确定位疾病的亚型、机制、分期和严重程度,并帮助临床医生做出手术和治疗应用的最佳决策。在这篇综述中,我们首先讨论了在 FECD 临床诊断中使用 scRNA-seq 的可行性和潜力,重点介绍了 FECD 最新临床治疗方法和新兴疗法的进展,整合了 scRNA-seq 结果和 FECD 患者的临床记录,并讨论了应用替代疗法临床管理这些病例的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploring single-cell RNA sequencing as a decision-making tool in the clinical management of Fuchs’ endothelial corneal dystrophy

Single-cell RNA sequencing (scRNA-seq) has enabled the identification of novel gene signatures and cell heterogeneity in numerous tissues and diseases. Here we review the use of this technology for Fuchs’ Endothelial Corneal Dystrophy (FECD). FECD is the most common indication for corneal endothelial transplantation worldwide. FECD is challenging to manage because it is genetically heterogenous, can be autosomal dominant or sporadic, and progress at different rates. Single-cell RNA sequencing has enabled the discovery of several FECD subtypes, each with associated gene signatures, and cell heterogeneity. Current FECD treatments are mainly surgical, with various Rho kinase (ROCK) inhibitors used to promote endothelial cell metabolism and proliferation following surgery. A range of emerging therapies for FECD including cell therapies, gene therapies, tissue engineered scaffolds, and pharmaceuticals are in preclinical and clinical trials. Unlike conventional disease management methods based on clinical presentations and family history, targeting FECD using scRNA-seq based precision-medicine has the potential to pinpoint the disease subtypes, mechanisms, stages, severities, and help clinicians in making the best decision for surgeries and the applications of therapeutics. In this review, we first discuss the feasibility and potential of using scRNA-seq in clinical diagnostics for FECD, highlight advances from the latest clinical treatments and emerging therapies for FECD, integrate scRNA-seq results and clinical notes from our FECD patients and discuss the potential of applying alternative therapies to manage these cases clinically.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
34.10
自引率
5.10%
发文量
78
期刊介绍: Progress in Retinal and Eye Research is a Reviews-only journal. By invitation, leading experts write on basic and clinical aspects of the eye in a style appealing to molecular biologists, neuroscientists and physiologists, as well as to vision researchers and ophthalmologists. The journal covers all aspects of eye research, including topics pertaining to the retina and pigment epithelial layer, cornea, tears, lacrimal glands, aqueous humour, iris, ciliary body, trabeculum, lens, vitreous humour and diseases such as dry-eye, inflammation, keratoconus, corneal dystrophy, glaucoma and cataract.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信